Advertisement
ICLR vs RGEN
Which Stock Would AI Choose? ICON plc (ICLR) vs. Repligen Corporation (RGEN) Stock Comparison
Key Takeaways
- ICLR (ICON plc) is a global contract research organization (CRO) with a large, visible backlog and consistent profitability, while RGEN (Repligen Corporation) is a life-sciences tools maker riding a bioprocessing recovery with faster organic growth.
- Both names carry "Buy" analyst consensus, but ICLR offers steadier earnings visibility, whereas RGEN carries more acquisition and margin-related volatility.
- Tickeron AI Verdict: ICLR currently ranks as the preferred ticker of the two, reflecting more consistent trend strength and stability.
- Recent quarters show ICLR beating estimates and lifting guidance, while RGEN posted a record quarter and closed its BioLife acquisition.
- For more detail on each name's latest developments, explore ICLR Major News and ICLR Today's Price Move, as well as RGEN Major News and RGEN Today's Price Move.
- To see how automated systems are positioning across these and other stocks, explore Trending AI Robots.
Introduction
Investors comparing ICLR and RGEN are weighing two distinct ways to participate in healthcare and life sciences. ICON plc is a leading contract research organization (CRO) that helps pharmaceutical and biotechnology companies run clinical trials, while Repligen Corporation supplies the bioprocessing equipment and consumables used to manufacture biologic drugs. Though both sit within the broader healthcare ecosystem, their business models, growth drivers, and risk profiles differ meaningfully. This stock comparison is most relevant to growth-oriented investors and traders evaluating relative performance, market positioning, and which name offers a steadier risk-reward profile in the current environment.
ICLR Overview and Recent Performance
ICLR (ICON plc) is a Dublin-headquartered contract research organization (CRO) that provides outsourced clinical development services, spanning clinical trial management, laboratory services, data analytics, and regulatory consulting. The company operates across more than 50 countries with over 40,000 employees, serving large pharmaceutical, biotechnology, and medical device clients.
In recent weeks, ICON reported third-quarter results that came in ahead of consensus, with non-GAAP earnings per share (EPS) and revenue both beating expectations. Management highlighted net business wins of roughly $3.15 billion, a book-to-bill ratio of 1.56 times, and a closing backlog near $24.5 billion, and raised its full-year revenue guidance. This performance triggered a wave of analyst price-target increases from several major firms, reinforcing a broader "Buy" consensus. Relative performance has improved as investors look past earlier accounting-related concerns and focus on steady bookings and demand across large pharma and biotech clients.
RGEN Overview and Recent Performance
RGEN (Repligen Corporation) is a Waltham, Massachusetts-based life-sciences company that develops and commercializes bioprocessing technologies across four franchises: filtration and fluid management, chromatography, process analytics, and proteins. Its customers are primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs).
Repligen recently delivered what management called a record quarter, with revenue up roughly 11% year over year to about $209 million and organic growth of approximately 12.5%. Adjusted EPS beat consensus by a wide margin, and the company raised its full-year revenue and earnings outlook. Sentiment has also been shaped by the closing of the BioLife acquisition, which expands Repligen's footprint in high-growth cell therapy, and by a recovery in bioprocessing demand. However, the stock carries ongoing margin headwinds in its filtration segment, GAAP (Generally Accepted Accounting Principles) net losses tied to acquisition costs, and a $1 billion convertible-notes transaction that introduces potential dilution.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each built around a distinct strategy, timeframe, and statistical profile. Because not every bot suits every market regime, Tickeron curates a dedicated Trending AI Robots page to spotlight the bots best aligned with current conditions. The bots available vary widely in trading style, holding period, and the set of tickers they cover, allowing users to compare performance metrics and statistics before engaging. Exploring this curated selection can help traders understand how automated, data-driven systems are approaching names like ICLR and RGEN relative to the broader market. To review the current lineup, visit the Trending AI Robots page.
Head-to-Head Comparison
The two companies differ fundamentally in what they sell and how they generate revenue. ICLR monetizes services tied to clinical trial execution, giving it a large contracted backlog and book-to-bill visibility that smooths near-term revenue. RGEN monetizes products and consumables consumed during biologic manufacturing, making it more sensitive to cyclical swings in bioprocessing demand but also a more direct play on manufacturing-volume growth.
On growth, RGEN currently shows faster organic expansion, helped by surging proteins and chromatography demand and the BioLife integration. ICLR shows more moderate single-digit revenue growth but stronger bottom-line consistency and GAAP profitability. Risk factors also diverge: ICON faces exposure to biotech funding cycles and lingering questions around earnings quality, while Repligen faces acquisition integration risk, filtration-segment softness, and near-term margin pressure. In sector terms, both are healthcare names, but ICON leans toward clinical development services and Repligen toward manufacturing tools, giving each a different sensitivity to the same biotech funding environment.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor ICLR at present. The assessment rests on more consistent trend strength, a large and visible backlog, a book-to-bill ratio well above 1.0, and steadier profitability, which together suggest greater stability and reduced downside variance relative to RGEN. Repligen offers a compelling growth catalyst through its BioLife acquisition and a recovering bioprocessing cycle, but its GAAP losses, margin headwinds, and recent convertible-notes dilution introduce more variability. The verdict reflects relative positioning rather than a definitive forecast, and market conditions can shift as new earnings and demand data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICLR is a Buy and RGEN is a Hold.
ICLR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ICLR turned positive on October 15, 2026. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICLR as a result. In 64 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
ICLR moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ICLR crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +17.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in 202 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 137 of 220 cases where ICLR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for ICLR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
ICLR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ICLR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.676) is normal, around the industry mean (65.986). ICLR's P/E Ratio (304.134) is considerably higher than the industry average of (3.066). Projected Growth (PEG Ratio) (0.533) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.626) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
RGEN saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for RGEN moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 58 similar instances where the indicator exited the overbought zone. In 49 of the 58 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 17 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 69 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 40 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
RGEN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
RGEN moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +7.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.764) is normal, around the industry mean (4.946). RGEN's P/E Ratio (240.905) is considerably higher than the industry average of (38.797). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ICLR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 90 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 88 | |
PRICE GROWTH RATING 1..100 | 35 | 42 | |
P/E GROWTH RATING 1..100 | 1 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ICLR's Valuation (93) in the Pharmaceuticals Other industry is in the same range as RGEN (99) in the Biotechnology industry. This means that ICLR’s stock grew similarly to RGEN’s over the last 12 months.
ICLR's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RGEN (100) in the Biotechnology industry. This means that ICLR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's SMR Rating (88) in the Biotechnology industry is in the same range as ICLR (90) in the Pharmaceuticals Other industry. This means that RGEN’s stock grew similarly to ICLR’s over the last 12 months.
ICLR's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as RGEN (42) in the Biotechnology industry. This means that ICLR’s stock grew similarly to RGEN’s over the last 12 months.
ICLR's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for RGEN (97) in the Biotechnology industry. This means that ICLR’s stock grew significantly faster than RGEN’s over the last 12 months.
| ICLR | RGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 72% | 6 days ago 68% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 73% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 81% |
| Advances ODDS (%) | 7 days ago 66% | 7 days ago 73% |
| Declines ODDS (%) | 1 day ago 69% | 3 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 62% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICLR’s FA Score shows that 1 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
- ICLR’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICLR’s TA Score shows that 6 TA indicator(s) are bullish while RGEN’s TA Score has 3 bullish TA indicator(s).
- ICLR’s TA Score: 6 bullish, 4 bearish.
- RGEN’s TA Score: 3 bullish, 6 bearish.
Price Growth
ICLR (@Medical Specialties) experienced а +11.36% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +1.41% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.30%. For the same industry, the average monthly price growth was -5.24%, and the average quarterly price growth was +42.12%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.70%. For the same industry, the average monthly price growth was -1.70%, and the average quarterly price growth was +10.08%.
Reported Earning Dates
ICLR is expected to report earnings on Feb 24, 2027.
RGEN is expected to report earnings on Feb 24, 2027.
Industries' Descriptions
@Medical Specialties (-2.30% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.70% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ICLR and
Correlation & Price change
A.I.dvisor indicates that over the last year, ICLR has been loosely correlated with RGEN. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ICLR jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To ICLR | 1D Price Change % | ||
|---|---|---|---|---|
| ICLR | 100% | -0.67% | ||
| RGEN - ICLR | 62% Loosely correlated | +3.08% | ||
| IQV - ICLR | 55% Loosely correlated | +1.61% | ||
| BRKR - ICLR | 54% Loosely correlated | +1.45% | ||
| TMO - ICLR | 47% Loosely correlated | +2.30% | ||
| AZTA - ICLR | 45% Loosely correlated | +4.47% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BTCC | 12.50 | 0.14 | +1.09% |
| Grayscale Bitcoin Covered Call ETF | |||
| AIO | 23.65 | 0.25 | +1.07% |
| Virtus Artificial Intelligence & Technology Opportunities Fund | |||
| NCLO | 24.91 | -0.01 | -0.04% |
| Nuveen AA-BBB CLO ETF | |||
| BSV | 76.75 | -0.05 | -0.07% |
| Vanguard Short-Term Bond ETF (BSV) | |||
| DBEZ | 61.02 | -0.08 | -0.13% |
| Xtrackers MSCI Eurozone Hedged Equity ETF (DBEZ) | |||